Substance / Medication

Haloperidol decanoate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
0
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Depot haloperidol decanoate for schizophrenia.
Quraishi S, David A · Cochrane Database Syst Rev · 2000
PMID: 10796438Meta-AnalysisFull text (PMC)
Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.
Rosenheck Robert A, Leslie Douglas L, Sint Kyaw J et al. · Psychiatr Serv · 2016
PMID: 27247177ObservationalFull text (PMC)
Methodological issues in a study of long-term maintenance therapy with quetiapine versus haloperidol decanoate.
Adetunji Babatunde, Basil Biju, Mathews Maju et al. · J Clin Psychiatry · 2006
PMID: 16649843Observational
Haloperidol Decanoate-Induced Pancytopenia: A Case Report.
Jagtiani Amit, Veigne Sandra, Gandhi Raghu et al. · Cureus · 2023
PMID: 38022280Case ReportFull text (PMC)
Adderall-Induced Persistent Psychotic Disorder Managed With Long-Acting Injectable Haloperidol Decanoate.
Desai Saral, Santos Erika L, Toma Anca E et al. · Cureus · 2022
PMID: 36039224Case ReportFull text (PMC)
Probable haloperidol decanoate-induced fever in an African American with benign ethnic neutropenia: A case report.
Youniss Lara, Thomas Michele, Davis Erica A K · Ment Health Clin · 2021
PMID: 34621607Case ReportFull text (PMC)
Drug-induced parkinsonism following chronic methamphetamine use by a patient on haloperidol decanoate.
Matthew Binoj J, Gedzior Joanna S · Int J Psychiatry Med · 2015
PMID: 26526398Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Haloperidol decanoate (substance)
SNOMED CT
412196004
UMLS CUI
C0062103

Clinical Data

This intervention maps to 6 entities in the Ltrl knowledge graph.

6
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.